Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1788967 | 0.90 | PAX8 (0.41) | PAX8 | |
| SCHEMBL9617279 | 0.84 | PAX8 (0.38) | PAX8 | |
| SCHEMBL2223107 | 0.84 | PAX8 (0.38) | PAX8 | |
| SCHEMBL1182041 | 0.84 | PAX8 (0.38) | PAX8 | |
| SCHEMBL424017 | 0.82 | MPI (0.35) | — | |
| SCHEMBL9807659 | 0.82 | PAX8 (0.36) | PAX8 | |
| SCHEMBL20889 | 0.82 | PAX8 (0.36) | PAX8 | |
| SCHEMBL2195882 | 0.81 | PAX8 (0.36) | PAX8 | |
| SCHEMBL17767400 | 0.81 | PAX8 (0.36) | PAX8 | |
| SCHEMBL16429714 | 0.81 | PAX8 (0.35) | PAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144021-A1 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2025-05-08 | — | — | US | disclosed |
| US-12226527-B2 | Gel formulations for local drug release | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2025-02-18 | — | — | US | disclosed |
| CN-115501172-A | Gel formulations for topical drug delivery | 丹麦技术大学 | 2022-12-23 | — | — | CN | disclosed |
| CN-107249570-B | Gel formulations for topical drug delivery | 丹麦技术大学 | 2022-08-09 | — | — | CN | disclosed |
| US-20210386669-A1 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2021-12-16 | — | — | US | disclosed |
| US-11065201-B2 | Gel formulations for local drug release | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2021-07-20 | — | — | US | disclosed |
| US-20180325819-A1 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2018-11-15 | — | — | US | disclosed |
| EP-3220887-A1 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE | Technical University of Denmark (DK) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016079331-A1 | GEL FORMULATIONS FOR ENHANCING THE EFFECT OF RADIOTHERAPY | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016079332-A1 | GEL FORMULATIONS FOR IMPROVING IMMUNOTHERAPY | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016079330-A1 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11065201-B2 | Gel formulations for local drug release | TREH, GALE, SLC2A8 | PAX8 1105/4885 |
| US-20180325819-A1 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE | TREH, GALE, SLC2A8 | PAX8 1105/4885 |
| US-20250144021-A1 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE | TREH, GALE, SLC2A8 | PAX8 1105/4885 |
| US-20210386669-A1 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE | TREH, GALE, SLC2A8 | PAX8 1105/4885 |
| US-12226527-B2 | Gel formulations for local drug release | TREH, GALE, SLC2A8 | PAX8 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.